{"nctId":"NCT00576823","briefTitle":"Alfuzosin Treatment in Children and Adolescents With Hydronephrosis of Neuropathic Etiology","startDateStruct":{"date":"2007-12"},"conditions":["Hydronephrosis","Neurogenic Bladder"],"count":25,"armGroups":[{"label":"Alfuzosin solution - 2-7 years","type":"EXPERIMENTAL","interventionNames":["Drug: Alfuzosin"]},{"label":"Alfuzosin solution - 8-16 years","type":"EXPERIMENTAL","interventionNames":["Drug: Alfuzosin"]},{"label":"Alfuzosin tablet - 8-16 years","type":"EXPERIMENTAL","interventionNames":["Drug: Alfuzosin"]}],"interventions":[{"name":"Alfuzosin","otherNames":["SL770499"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Children and adolescents of either gender 2 - 16 years of age with a detrusor Leak Point Pressure (LPP) of 40 cm water or greater and with newly diagnosed or progressive hydronephrosis either Society of Fetal Urology (SFU) grade 1, 2 or 3 due to neuropathic bladder dysfunction.\n\nExclusion Criteria:\n\n* Hydronephrosis of non-neuropathic etiology.\n* Urological surgery in the last 4 months prior to the study.\n* Urethral dilatation in the last 3 months prior to the baseline urodynamic assessment.\n* α-blocker therapy in the last 4 weeks prior to the baseline urodynamic assessment.\n* Detrusor injections of botulinum toxin in the last 6 months.\n* Urological diseases/conditions other than functional bladder obstruction of neuropathic etiology, that can lead to upper urinary tract dilatation (e.g., bladder anomalies, ureterocele).\n* History of intolerance to α-blocker therapy.\n* Orthostatic hypotension.\n* History of risk factors for Torsade de pointes (e.g., family history of Long QT Syndrome).\n\nThe above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.","healthyVolunteers":false,"sex":"ALL","minimumAge":"2 Years","maximumAge":"16 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With a Decrease From Baseline ≥ 1 in the Society of Fetal Urology (SFU) Grade of Hydronephrosis","description":"Hydronephrosis was investigated by ultrasound and graded using SFU classification at each time point.\n\n'Complete response' was assessed when bilateral hydronephrosis at baseline and grade decrease from baseline ≥ 1 for both kidneys, or, unilateral hydronephrosis at baseline and grade decrease from baseline ≥ 1 for the affected kidney without worsening of the other kidney.\n\n'Partial response' was assessed when bilateral hydronephrosis at baseline and grade decrease from baseline ≥ 1 for one kidney without worsening of the other kidney.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Symptomatic Urinary Tract Infection (UTI) Episodes","description":"When a patient presented with symptoms such as pain, fever or hematuria (discretion of the Investigator), an urinalysis was performed including a dipstick and a quantitative urine culture.\n\nA symptomatic UTI was defined as the presence of symptoms and a positive culture with \\> 100 000 Colony Forming Units (CFUs) with a single organism.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Symptomatic Urinary Tract Infection (UTI) Episodes","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":12},"commonTop":["CYSTITIS","NASOPHARYNGITIS","PYREXIA","PHARYNGITIS","UPPER RESPIRATORY TRACT INFECTION"]}}}